fbpx
January 31, 2023

M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms

Submit Comments by 04/01/2023 Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the FDA considers your comment […]
January 31, 2023

La FDA publica una guía para ayudar a aumentar el suministro de ibuprofeno en suspensión oral en hospitales y centros de salud

[20/01/2023] En un esfuerzo por mejorar el suministro de ibuprofeno preparado en suspensión oral en medio de una demanda récord, la FDA está publicando una guía […]
January 31, 2023

Cefepime – Injection products

Recognized Interpretive Criteria Exceptions to the recognized standard of CLSI M100 Minimum InhibitoryConcentrations(mcg/mL) Disk Diffusion(zone diameter in mm) Pathogen S I R S I R Enterobacterales […]
January 31, 2023

Cefiderocol Injection

FDA Identified Breakpoints Minimum Inhibitory Concentrations (mcg/mL) Disk Diffusion (zone diameters in mm) Pathogen S I R S I R Enterobacteralesa,b M-100 standard is recognized Pseudomonas […]
January 31, 2023

Radioactive Drug Research Committee: Human Research Without An Investigational New Drug Application

Docket Number: FDA-2009-D-0125 Issued by: Guidance Issuing Office Center for Biologics Evaluation and Research Center for Drug Evaluation and Research This guidance is intended to provide […]
January 30, 2023

New Drug Therapy Approvals 2019

IMPACT  INNOVATION  PREDICTABILITY  ACCESSFDA’s Center for Drug Evaluation and ResearchJanuary 2020 New Drug Therapy Approvals 2019 (PDF-2.45MB) Content Introduction2019: Another Strong Year for Innovation and AdvancesNovel […]
January 30, 2023

Edgewell Personal Care Issues Voluntary Nationwide Recall of Banana Boat Hair & Scalp Sunscreen Due to the Presence of Benzene – UPDATED

Summary Company Announcement Date: January 27, 2023 FDA Publish Date: January 30, 2023 Product Type: Drugs Reason for Announcement: Recall Reason Description Due to presence of […]
January 30, 2023

Update on In-Person Face-to-Face Formal Meetings with FDA

The PDUFA VII and BsUFA III commitment letters provide an update to the definition of face-to-face formal meetings with industry. This update clarifies that a face-to-face […]
January 30, 2023

Acromegaly: Developing Drugs for Treatment

Docket Number: FDA-2022-D-2658 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research The purpose of this guidance is to provide recommendations to sponsors regarding […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0